---
document_datetime: 2023-09-21 21:01:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/lorviqua-epar-all-authorised-presentations_en.pdf
document_name: lorviqua-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.832851
conversion_datetime: 2025-12-15 06:09:53.611318
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented)   | Strength   | Pharmaceutical     | Route of       | Immediate Packaging   | Pack size   |
|------------------|--------------|------------|--------------------|----------------|-----------------------|-------------|
|                  | name         |            | Form               | Administration |                       |             |
| EU/1/19/1355/002 | Lorviqua     | 100 mg     | Film-coated tablet | Oral use       | blister (OPA/alu/PVC) | 30 tablets  |
| EU/1/19/1355/003 | Lorviqua     | 25 mg      | Film-coated tablet | Oral use       | blister (OPA/alu/PVC) | 90 tablets  |